HUE037491T2 - A semi-solid aqueous formulation containing tapentadol - Google Patents

A semi-solid aqueous formulation containing tapentadol

Info

Publication number: HUE037491T2
Authority: HU; Hungary
Prior art keywords: semi; formulation containing; aqueous formulation; solid aqueous; containing tapentadol
Prior art date: 2011-03-04

Application number

HUE12710026A

Other languages

Hungarian (hu)

Inventor

Ulrich Reinhold

Marc Schiller

Eva Wulsten

Sabine Inghelbrecht

Roger EMBRECHTS

Ulrich Feil

Original Assignee

Gruenenthal Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-03-04

Filing date

2012-03-02

Publication date

2018-09-28

2012-03-02 Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh

2018-09-28 Publication of HUE037491T2 publication Critical patent/HUE037491T2/en

Links

239000013011 aqueous formulation Substances 0.000 title 1
239000007787 solid Substances 0.000 title 1
KWTWDQCKEHXFFR-SMDDNHRTSA-N tapentadol Chemical compound CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-SMDDNHRTSA-N 0.000 title 1
229960005126 tapentadol Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oil, Petroleum & Natural Gas (AREA)
Engineering & Computer Science (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)
Dispersion Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

HUE12710026A 2011-03-04 2012-03-02 A semi-solid aqueous formulation containing tapentadol HUE037491T2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161449329P	2011-03-04	2011-03-04
EP11003603		2011-05-03

Publications (1)

Publication Number	Publication Date
HUE037491T2 true HUE037491T2 (en)	2018-09-28

Family

ID=44652117

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HUE12710026A HUE037491T2 (en)	2011-03-04	2012-03-02	A semi-solid aqueous formulation containing tapentadol

Country Status (24)

Country	Link
US (3)	US9446008B2 (en)
EP (3)	EP3290029B1 (en)
JP (3)	JP6027549B2 (en)
KR (2)	KR101911362B1 (en)
CN (1)	CN103501774A (en)
AU (2)	AU2012224954C1 (en)
BR (1)	BR112013022556A8 (en)
CA (1)	CA2828637C (en)
CY (1)	CY1119725T1 (en)
DK (1)	DK2680834T3 (en)
EA (2)	EA033171B1 (en)
ES (2)	ES2910085T3 (en)
HR (1)	HRP20171836T1 (en)
HU (1)	HUE037491T2 (en)
IL (2)	IL227826B (en)
LT (1)	LT2680834T (en)
MX (2)	MX344473B (en)
NO (1)	NO2680834T3 (en)
PL (1)	PL2680834T3 (en)
PT (2)	PT3766489T (en)
RS (1)	RS56692B1 (en)
SI (1)	SI2680834T1 (en)
WO (1)	WO2012119729A1 (en)
ZA (1)	ZA201306480B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2910085T3 (en) *	2011-03-04	2022-05-11	Gruenenthal Gmbh	Semisolid aqueous pharmaceutical composition containing tapentadol
MX388963B (en)	2011-03-04	2025-03-20	Gruenenthal Gmbh	Aqueous pharmaceutical formulation of tapentadol for oral administration
US9395306B2 (en)	2011-08-05	2016-07-19	Halliburton Energy Services, Inc.	Methods for monitoring fluids within or produced from a subterranean formation during acidizing operations using opticoanalytical devices
US8997860B2 (en)	2011-08-05	2015-04-07	Halliburton Energy Services, Inc.	Methods for monitoring the formation and transport of a fracturing fluid using opticoanalytical devices
US8619256B1 (en)	2012-09-14	2013-12-31	Halliburton Energy Services, Inc.	Systems and methods for monitoring the properties of a fluid cement composition in a flow path
US20140076550A1 (en)	2012-09-14	2014-03-20	Halliburton Energy Services, Inc.	Systems and Methods for Detecting Microannulus Formation and Remediation
US9228940B2 (en)	2012-09-14	2016-01-05	Halliburton Energy Services, Inc.	Systems, methods, and apparatuses for in situ monitoring of cement fluid compositions and setting processes thereof
EP3027214A1 (en) *	2013-08-02	2016-06-08	ratiopharm GmbH	Composition comprising tapentadol in a dissolved form
EP2845625A1 (en)	2013-09-04	2015-03-11	Grünenthal GmbH	Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
PE20171651A1 (en)	2015-03-27	2017-11-13	Gruenenthal Chemie	STABLE FORMULATION FOR PARENTERAL ADMINISTRATION OF TAPENTADOL
EP3515412B1 (en)	2016-09-23	2025-04-23	Grünenthal GmbH	Stable formulation for parenteral administration of tapentadol
JP2021532112A (en) *	2018-07-24	2021-11-25	ドクトア・アウグスト・ボルフ・ゲーエムベーハー・ウント・コンパニー・カー・ゲー−アルツナイミツテル	Topical emulsion of anticholinergic compounds
BR112021004199A2 (en)	2018-09-07	2021-05-25	R.P. Scherer Technologies, Llc	stabilization of solid or semi-solid lipid-based dosage forms through curing and addition of low hlb surfactant(s)
JP7646560B2 (en)	2019-03-18	2025-03-17	サンスターアメリカスインク	Oral Care Compositions

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4775678A (en) *	1984-10-01	1988-10-04	Schering Corporation	Clotrimazole cream
DE4426245A1 (en)	1994-07-23	1996-02-22	Gruenenthal Gmbh	1-phenyl-3-dimethylamino-propane compounds with pharmacological activity
US6183758B1 (en) *	1998-01-29	2001-02-06	Highland Laboratories, Inc.	Phytochemicals, nutrients & medication absorption &/or treatment
US6399087B1 (en)	2000-12-20	2002-06-04	Amphastar Pharmaceuticals, Inc.	Propofol formulation with enhanced microbial inhibition
DE10109763A1 (en)	2001-02-28	2002-09-05	Gruenenthal Gmbh	Pharmaceutical salts
US20050176790A1 (en)	2001-02-28	2005-08-11	Johannes Bartholomaus	Pharmaceutical salts
PE20030527A1 (en)	2001-10-24	2003-07-26	Gruenenthal Chemie	DELAYED-RELEASE PHARMACEUTICAL FORMULATION CONTAINING 3- (3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL) PHENOL OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME AND ORAL TABLETS CONTAINING IT
CA2479350A1 (en)	2002-03-15	2003-09-25	Cypress Bioscience, Inc.	Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
US20030191187A1 (en)	2002-04-01	2003-10-09	Lee Fang Yu	Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
RU2359698C2 (en)	2002-09-13	2009-06-27	Сайдекс, Инк.	Capsules containing water filling compositions, stabilised with derivative of cyclodextrin
US20040180915A1 (en)	2003-03-14	2004-09-16	Xanodyne Pharmacal, Inc.	Methadone-containing compositions for parenteral administration and method of use thereof
US20060111382A1 (en)	2004-05-17	2006-05-25	Pharmacofore, Inc.	Compositions and methods for treating or preventing pain
PT1612203E (en)	2004-06-28	2007-08-20	Gruenenthal Gmbh	Crystalline forms of (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
BRPI0513300B1 (en)	2004-07-01	2018-11-06	Gruenenthal Gmbh	oral dosage form, protected from abuse, containing (1r, 2r) -3- (3-dimethylamino-1-ethyl-2-methyl-lpropyl) -phenol
EP1893190A4 (en)	2005-04-28	2010-07-28	Theraquest Biosciences Llc	Methods and compositions for treating pain
TWI329334B (en)	2005-12-02	2010-08-21	Chung Shan Inst Of Science	Manufacture method of electromagnetic interference layer for the plasma display panel
WO2007127158A2 (en) *	2006-04-25	2007-11-08	Croda, Inc	Modification of percutaneous absorption of topically active materials
ATE502629T1 (en) *	2006-04-28	2011-04-15	Gruenenthal Gmbh	PHARMACEUTICAL COMBINATION WITH 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL) PHENOL AND AN NSAID
PL2012764T3 (en)	2006-04-28	2011-04-29	Gruenenthal Gmbh	Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and paracetamol
BRPI0714671B8 (en)	2006-07-24	2023-03-21	Janssen Pharmaceutica Nv	PREPARATION OF (2R,3R)-3-(3-METHOXYPHENYL)-N,N,2-TRIMETHYLPENTANAMINE AND INTERMEDIATE COMPOUNDS
DE102007012165A1 (en)	2007-03-12	2008-09-18	Grünenthal GmbH	Use of 1-phenyl-3-dimethylamino-propane compounds for the therapy of neuropathy pain
EP1985292A1 (en)	2007-04-23	2008-10-29	Grünenthal GmbH	Titration of tapentadol
RS55769B1 (en)	2007-11-23	2017-07-31	Gruenenthal Gmbh	TAPENTADOL COMPOSITIONS
CA2713128C (en)	2008-01-25	2016-04-05	Gruenenthal Gmbh	Pharmaceutical dosage form
RU2673882C1 (en)	2008-10-30	2018-12-03	Грюненталь Гмбх	New and effective medicinal forms of tapentadol
WO2010100477A2 (en)	2009-03-03	2010-09-10	Shire Llc	Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof
US20100272815A1 (en)	2009-04-28	2010-10-28	Actavis Group Ptc Ehf	Amorphous form of tapentadol hydrochloride
US20110190267A1 (en) *	2010-01-05	2011-08-04	Shire Pharmaceuticals, Inc.	Prodrugs of opioids and uses thereof
ES2829386T3 (en) *	2010-03-30	2021-05-31	Phosphagenics Ltd	Transdermal administration patch
GB201006200D0 (en) *	2010-04-14	2010-06-02	Ayanda As	Composition
US20120270848A1 (en) *	2010-10-22	2012-10-25	Galleon Pharmaceuticals, Inc.	Novel Compositions and Therapeutic Methods Using Same
ES2910085T3 (en) *	2011-03-04	2022-05-11	Gruenenthal Gmbh	Semisolid aqueous pharmaceutical composition containing tapentadol

2012
- 2012-03-02 ES ES20188822T patent/ES2910085T3/en active Active
- 2012-03-02 HU HUE12710026A patent/HUE037491T2/en unknown
- 2012-03-02 BR BR112013022556A patent/BR112013022556A8/en not_active Application Discontinuation
- 2012-03-02 EP EP17189139.3A patent/EP3290029B1/en not_active Not-in-force
- 2012-03-02 US US13/410,837 patent/US9446008B2/en active Active
- 2012-03-02 DK DK12710026.1T patent/DK2680834T3/en active
- 2012-03-02 PT PT201888229T patent/PT3766489T/en unknown
- 2012-03-02 KR KR1020137026185A patent/KR101911362B1/en not_active Expired - Fee Related
- 2012-03-02 CN CN201280011678.9A patent/CN103501774A/en active Pending
- 2012-03-02 MX MX2013010100A patent/MX344473B/en active IP Right Grant
- 2012-03-02 NO NO12710026A patent/NO2680834T3/no unknown
- 2012-03-02 PL PL12710026T patent/PL2680834T3/en unknown
- 2012-03-02 ES ES12710026.1T patent/ES2654407T3/en active Active
- 2012-03-02 KR KR1020187029861A patent/KR102039320B1/en not_active Expired - Fee Related
- 2012-03-02 EA EA201600442A patent/EA033171B1/en not_active IP Right Cessation
- 2012-03-02 WO PCT/EP2012/000906 patent/WO2012119729A1/en not_active Ceased
- 2012-03-02 HR HRP20171836TT patent/HRP20171836T1/en unknown
- 2012-03-02 JP JP2013555798A patent/JP6027549B2/en not_active Expired - Fee Related
- 2012-03-02 RS RS20171334A patent/RS56692B1/en unknown
- 2012-03-02 PT PT127100261T patent/PT2680834T/en unknown
- 2012-03-02 LT LTEP12710026.1T patent/LT2680834T/en unknown
- 2012-03-02 MX MX2016016703A patent/MX374468B/en unknown
- 2012-03-02 EP EP12710026.1A patent/EP2680834B1/en active Active
- 2012-03-02 SI SI201231143T patent/SI2680834T1/en unknown
- 2012-03-02 AU AU2012224954A patent/AU2012224954C1/en not_active Ceased
- 2012-03-02 EP EP20188822.9A patent/EP3766489B1/en active Active
- 2012-03-02 CA CA2828637A patent/CA2828637C/en not_active Expired - Fee Related
- 2012-03-02 EA EA201300988A patent/EA025194B1/en not_active IP Right Cessation
2013
- 2013-08-06 IL IL227826A patent/IL227826B/en active IP Right Grant
- 2013-08-28 ZA ZA2013/06480A patent/ZA201306480B/en unknown
2016
- 2016-08-10 US US15/232,841 patent/US20160346229A1/en not_active Abandoned
- 2016-10-12 JP JP2016200663A patent/JP6259042B2/en not_active Expired - Fee Related
2017
- 2017-01-04 AU AU2017200040A patent/AU2017200040B2/en not_active Ceased
- 2017-11-29 JP JP2017228602A patent/JP6670283B2/en not_active Expired - Fee Related
2018
- 2018-01-03 CY CY20181100006T patent/CY1119725T1/en unknown
- 2018-01-10 US US15/867,330 patent/US20180133174A1/en not_active Abandoned
- 2018-03-26 IL IL258357A patent/IL258357A/en unknown

Also Published As

Publication number	Publication date
DK2680834T3 (en)	2017-12-04
AU2017200040A1 (en)	2017-02-02
EP3290029A1 (en)	2018-03-07
AU2012224954C1 (en)	2017-04-06
EA033171B1 (en)	2019-09-30
MX2013010100A (en)	2013-10-01
US20160346229A1 (en)	2016-12-01
MX344473B (en)	2016-12-16
HRP20171836T1 (en)	2017-12-29
KR101911362B1 (en)	2018-10-25
JP6027549B2 (en)	2016-11-16
AU2017200040B2 (en)	2018-09-06
BR112013022556A2 (en)	2016-12-06
CA2828637C (en)	2019-06-11
KR20180116463A (en)	2018-10-24
BR112013022556A8 (en)	2018-01-16
IL227826A0 (en)	2013-09-30
CY1119725T1 (en)	2018-06-27
US9446008B2 (en)	2016-09-20
KR20140013020A (en)	2014-02-04
WO2012119729A1 (en)	2012-09-13
JP6670283B2 (en)	2020-03-18
AU2012224954A1 (en)	2013-09-19
AU2012224954B2 (en)	2016-10-20
ES2910085T3 (en)	2022-05-11
JP2014506900A (en)	2014-03-20
ES2654407T3 (en)	2018-02-13
EP2680834B1 (en)	2017-10-18
PT3766489T (en)	2022-04-07
ZA201306480B (en)	2014-05-28
EA201600442A1 (en)	2017-02-28
EP3290029B1 (en)	2020-09-02
NO2680834T3 (en)	2018-03-17
IL227826B (en)	2018-04-30
KR102039320B1 (en)	2019-11-01
CN103501774A (en)	2014-01-08
SI2680834T1 (en)	2018-01-31
LT2680834T (en)	2018-01-10
IL258357A (en)	2018-05-31
JP6259042B2 (en)	2018-01-10
EP3766489B1 (en)	2022-03-16
EP2680834A1 (en)	2014-01-08
PL2680834T3 (en)	2018-03-30
MX374468B (en)	2025-03-06
US20120225950A1 (en)	2012-09-06
JP2018065839A (en)	2018-04-26
RS56692B1 (en)	2018-03-30
EA201300988A1 (en)	2014-06-30
PT2680834T (en)	2018-01-25
EP3766489A1 (en)	2021-01-20
EA025194B1 (en)	2016-11-30
CA2828637A1 (en)	2012-09-13
JP2017039756A (en)	2017-02-23
US20180133174A1 (en)	2018-05-17

Publication	Publication Date	Title
HUE037491T2 (en)	2018-09-28	A semi-solid aqueous formulation containing tapentadol
CO6801708A2 (en)	2013-11-29	A support agent
CO6801645A2 (en)	2013-11-29	New immunoconjugates
HUE046557T2 (en)	2020-03-30	An aqueous pharmaceutical composition containing tapentadol for oral use
EP2673344A4 (en)	2016-08-17	STABLE BIOCARBURANT
CO6811882A2 (en)	2013-12-16	A support agent
DK2667892T3 (en)	2019-05-13	RSV vaccination program
EP2708229A4 (en)	2014-11-19	NON AQUEOUS STAMP
BR112014000015A2 (en)	2017-02-07	formulation
PL2361850T3 (en)	2014-06-30	Dispenser
BR112015004825A2 (en)	2018-05-22	aqueous microbicidal composition.
IL230038B (en)	2019-11-28	herbicide preparation
CO7010807A2 (en)	2014-07-31	Dispenser
DK2903652T3 (en)	2022-07-04	HYDROXYLED POLYAMINE DERIVATIVES AS TRANSFECTION REAGENTS
DK2903651T3 (en)	2022-01-17	CARBOXYLED POLYAMINE DERIVATIVES AS TRANSFECTION REAGENTS
EP2770828A4 (en)	2015-04-15	FORMULATION
EP2762139A4 (en)	2015-03-18	ANTIFUNGAL AGENT
BR112014025158A2 (en)	2017-07-18	method to produce a compound.
EP2782968C0 (en)	2024-06-19	AQUEOUS COATING COMPOUNDS
HRP20151339T8 (en)	2016-02-26	PREPARATION BASED ON UBIDEKARENON
BR112013031537A2 (en)	2017-03-01	aqueous gel.
DK2785675T5 (en)	2017-06-26	5,5-DIMETHYL-2-PROPYL-HEXAHYDRO-2,4A-METHANONAPHTHALENE-1-ON AS SCENTER
ITMC20110012U1 (en)	2012-12-16	FOLDING SHOE
BR302012002914S1 (en)	2013-12-03	CONFIGURATION APPLIED TO BOTTLE.
ITRM20110570A1 (en)	2012-01-27	FIXATIVE SOLUTION FOR TANATOPRASSI